Literature DB >> 12825937

Dual protein farnesyltransferase-geranylgeranyltransferase-I inhibitors as potential cancer chemotherapeutic agents.

S Jane deSolms1, Terrence M Ciccarone, Suzanne C MacTough, Anthony W Shaw, Carolyn A Buser, Michelle Ellis-Hutchings, Christine Fernandes, Kelly A Hamilton, Hans E Huber, Nancy E Kohl, Robert B Lobell, Ronald G Robinson, Nancy N Tsou, Eileen S Walsh, Samuel L Graham, Lorena S Beese, Jeffrey S Taylor.   

Abstract

A series of novel diaryl ether lactams have been identified as very potent dual inhibitors of protein farnesyltransferase (FTase) and protein geranylgeranyltransferase I (GGTase-I), enzymes involved in the prenylation of Ras. The structure of the complex formed between one of these compounds and FTase has been determined by X-ray crystallography. These compounds are the first reported to inhibit the prenylation of the important oncogene Ki-Ras4B in vivo. Unfortunately, doses sufficient to achieve this endpoint were rapidly lethal.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12825937     DOI: 10.1021/jm020587n

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  12 in total

Review 1.  Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?

Authors:  Adrienne D Cox; Channing J Der; Mark R Philips
Journal:  Clin Cancer Res       Date:  2015-04-15       Impact factor: 12.531

Review 2.  Unraveling the mechanism of the farnesyltransferase enzyme.

Authors:  Sérgio Filipe Sousa; Pedro Alexandrino Fernandes; Maria João Ramos
Journal:  J Biol Inorg Chem       Date:  2004-12-21       Impact factor: 3.358

3.  Simvastatin interacts synergistically with tipifarnib to induce apoptosis in leukemia cells through the disruption of RAS membrane localization and ERK pathway inhibition.

Authors:  Tamer A Ahmed; John Hayslip; Markos Leggas
Journal:  Leuk Res       Date:  2014-09-16       Impact factor: 3.156

4.  The chaperone SmgGDS-607 has a dual role, both activating and inhibiting farnesylation of small GTPases.

Authors:  Desirée García-Torres; Carol A Fierke
Journal:  J Biol Chem       Date:  2019-06-13       Impact factor: 5.157

5.  Protein Lipidation: Occurrence, Mechanisms, Biological Functions, and Enabling Technologies.

Authors:  Hong Jiang; Xiaoyu Zhang; Xiao Chen; Pornpun Aramsangtienchai; Zhen Tong; Hening Lin
Journal:  Chem Rev       Date:  2018-01-02       Impact factor: 60.622

6.  Amide-substituted farnesylcysteine analogs as inhibitors of human isoprenylcysteine carboxyl methyltransferase.

Authors:  James L Donelson; Heather B Hodges; Daniel D Macdougall; Brian S Henriksen; Christine A Hrycyna; Richard A Gibbs
Journal:  Bioorg Med Chem Lett       Date:  2006-06-13       Impact factor: 2.823

7.  Protein farnesyltransferase: flexible docking studies on inhibitors using computational modeling.

Authors:  Wayne C Guida; Andrew D Hamilton; Justin W Crotty; Saïd M Sebti
Journal:  J Comput Aided Mol Des       Date:  2006-05-12       Impact factor: 3.686

Review 8.  Small change, big effect: Taking RAS by the tail through suppression of post-prenylation carboxylmethylation.

Authors:  Hiu Yeung Lau; Mei Wang
Journal:  Small GTPases       Date:  2018-01-25

9.  Targeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-induced lung cancer.

Authors:  Meng Liu; Anna-Karin M Sjogren; Christin Karlsson; Mohamed X Ibrahim; Karin M E Andersson; Frida J Olofsson; Annika M Wahlstrom; Martin Dalin; Huiming Yu; Zhenggang Chen; Shao H Yang; Stephen G Young; Martin O Bergo
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-22       Impact factor: 11.205

10.  Nanoformulation of Geranylgeranyltransferase-I Inhibitors for Cancer Therapy: Liposomal Encapsulation and pH-Dependent Delivery to Cancer Cells.

Authors:  Jie Lu; Kohei Yoshimura; Koichi Goto; Craig Lee; Ken Hamura; Ohyun Kwon; Fuyuhiko Tamanoi
Journal:  PLoS One       Date:  2015-09-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.